(NewsDirect)
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managingdirector Steven Yatomi-Clarke sits down with Jonathan Jackson in theProactive studio ahead of a presentation of the results of its PTX-100Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) inCalifornia from June 6 to 8. The Phase 1b study targeted patients withrelapsed and refractory T-cell lymphomas (r/r TCLs) and successfullymet its primary objectives of demonstrating safety and determiningpharmacokinetics and pharmacodynamics. Additionally, the study showeda promising preliminary efficacy with a 45% overall response rate,where five out of 11 evaluable patients responded positively to thetreatment. T-cell lymphomas are a rare type of non-Hodgkin lymphoma,classified as an orphan disease with about 30,000 cases. PTX-100 hasreceived Orphan Drug Designation from the US FDA, highlighting theneed for more effective treatments for TCLs, particularly for relapsedand refractory cases. The T-Cell Lymphoma Forum is a specialisedconference focused on advancements in TCL treatment, bringing togetherclinicians, scientists and industry professionals. Yatomi-Clarke,emphasised the importance of this platform for sharing criticalresearch and the significance of PTX-100 in addressing an unmetmedical need. The company plans to advance to a Phase 2 trial in r/rTCL, expected to commence in Q3 2024.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.